Monitoring impurities in biopharmaceuticals produced by recombinant technology

Area of Science:

• Biopharmaceutical Manufacturing
• Analytical Chemistry
• Regulatory Science

Background:

• Recombinant technology and biotherapeutic production present unique challenges for impurity control.
• Impurities and contaminants can significantly impact product quality, efficacy, and patient safety, even at trace levels.

Purpose of the Study:

• To provide a comprehensive understanding of potential product- and process-related impurities in biotherapeutics.
• To describe current and emerging methodologies for controlling and monitoring these critical impurities.

Main Methods:

• Literature review and synthesis of existing knowledge on biopharmaceutical impurities.
• Analysis of regulatory guidelines concerning impurity characterization and control.
• Overview of analytical techniques for impurity detection and quantification.

Main Results:

• Identification of diverse categories of product- and process-related impurities.
• Discussion of the impact of impurities on biotherapeutic safety and efficacy.
• Presentation of established and novel strategies for impurity management.

Conclusions:

• Effective control and monitoring of impurities are essential for biopharmaceutical quality and patient safety.
• A thorough understanding of impurity profiles guides the development of robust manufacturing processes.
• Continuous advancement in analytical methodologies is crucial for meeting evolving regulatory expectations.